Absorption, metabolism, excretion, and safety of [14C]almonertinib in healthy Chinese subjects

Chen Zhou; Lijun Xie; Wei Liu; Lingling Zhang; Sufeng Zhou; Lu Wang; Juan Chen; Huan Li; Yuqing Zhao; Bei Zhu; Sijia Ding; Chen Zhang; Feng Shao

doi:10.21037/atm-21-1606

Absorption, metabolism, excretion, and safety of [¹⁴C]almonertinib in healthy Chinese subjects

Ann Transl Med. 2021 May;9(10):867. doi: 10.21037/atm-21-1606.

Authors

Chen Zhou¹, Lijun Xie¹, Wei Liu², Lingling Zhang³, Sufeng Zhou¹, Lu Wang¹, Juan Chen¹, Huan Li³, Yuqing Zhao¹, Bei Zhu¹, Sijia Ding¹, Chen Zhang², Feng Shao¹

Affiliations

¹ Phase I Clinical Trial Unit, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
² Nuclear Medicine Department, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
³ Lab Testing Division, Department of DMPK Service, WuXi AppTec Co., Ltd., Nanjing, China.

Abstract

Background: Almonertinib Mesilate Tablets (HS-10296, Hansoh Pharma, Shanghai, China) is a novel and selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). A phase I study of almonertinib in patients with non-small cell lung cancer (NSCLC) demonstrated a linear metabolic trend, a good tolerability/safety profile, and preliminary antitumor activity. However, the metabolism, excretion, and substance balance of almonertinib has not been clearly determined. Here, we investigated the pharmacokinetic characteristics and safety profile of almonertinib following a single oral dose (110 mg/50 µCi) in healthy Chinese male participants.

Methods: Total radioactivity (TRA) in whole blood, plasma, urine, and feces was measured by utilizing a liquid scintillation counter to obtain almonertinib substance balance data. The pharmacokinetic parameters of [¹⁴C]almonertinib and the parent drug almonertinib in whole blood and plasma were analyzed with noncompartmental analysis in the WinNonlin software (Pharsight Corp). The major metabolites in plasma, urine, and feces were analyzed by high-performance liquid chromatography (HPLC) coupled with an online or offline isotope detector. The safety of the drug was evaluated after administration.

Results: The safety and tolerability of a single oral dose of 110 mg/50 µCi [¹⁴C] almonertinib suspension were good in healthy Chinese male participants. There was no significant abnormality or special adverse reaction. TRA peaked quickly in plasma, with a T_max of 4.0 h; however, TRA was cleared slowly in vivo, with a mean terminal elimination phase (half-life, T_1/2) of up to 863 h. In addition to the parent drug, a total of 26 metabolites in blood, urine, and feces were analyzed. In plasma, parent drug was the major drug-related component, accounting for 69.97% of TRA, and M440 (almonertinib-M2 demethyl product) was the major metabolite, accounting for 5.08% of TRA; in urine, parent drug accounted for 0.48% of the dose administered and HAS-719 was the major metabolite, accounting for 1.20% of the administered dose; in feces, parent drug was about 8.61% of the dose administered and HAS-719 was the major metabolite, accounting for 12.33% of the administered dose, which was followed by M541a/M470a and M617/M575, accounting for 11.8% and 6.76% of the administered dose, respectively.

Conclusions: Almonertinib has a good safety profile, with parent drug as its main circulating component. almonertinib is extensively metabolized in vivo before excretion and is excreted as a parent drug and metabolites mainly via feces.

Trial registration: The trial registration number: CTR20192291.

Keywords: 14C; Almonertinib; HS-10296; excretion; metabolism; pharmacokinetics.